ArticleTherapeutic advances in gastroenterology2010
Immunomodulators for all patients with inflammatory bowel disease?
Article in Therapeutic advances in gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease.Digestive diseases and sciences · 2015Trial
- Beyond rheumatology: Reconsidering methotrexate for Crohn's disease in the biologic era.World journal of gastroenterology · 2026Article
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- NDP52 and its emerging role in pathogenesis.Cell death & disease · 2025Review
- Collagen Peptides andFood science & nutrition · 2025Article
- Surgeons Knowledge, Attitude, and Practice Toward Preoperative Inflammatory Bowel Disease Medications and Post-Operative Complications.Therapeutics and clinical risk management · 2025Article
- Aspergillus awamori: potential antioxidant, anti-inflammatory, and anti-apoptotic activities in acetic acid-induced ulcerative colitis in rats.Inflammopharmacology · 2024Article
- Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects.Journal of clinical medicine · 2024Review
- Enteric Nervous System Alterations in Inflammatory Bowel Disease: Perspectives and Implications.Gastrointestinal disorders (Basel, Switzerland) · 2024Article
- Review
- Isolated Gastric Crohn's Disease: A Growing Tendency.European journal of case reports in internal medicine · 2024Article
- Long-term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: A real-world experience.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Effectiveness and tolerability of methotrexate monotherapy in Crohn's disease patients: a multicenter observational study.Therapeutic advances in gastroenterology · 2023Article
- Inflammatory Bowel Disease Management during the COVID-19 Pandemic: A Literature Review.Middle East journal of digestive diseases · 2022Review
- Formulation of a thermo-sensitive hydro-gel for ulcerative colitis treatment.Bioinformation · 2022Article
- Shooting yourself in the foot: How immune cells induce antibiotic tolerance in microbial pathogens.PLoS pathogens · 2021Review
- Role of Oxidative Stress and Inflammatory Cytokines (TNF-α and IL-6) in Acetic Acid-Induced Ulcerative Colitis in Rats: Ameliorated byLife (Basel, Switzerland) · 2021Article
- Article
- Medical Management of Crohn's Disease.Cureus · 2020Review
- A Small Aromatic Compound Has Antifungal Properties and Potential Anti-Inflammatory Effects against Intestinal Inflammation.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent insight into the pathogenesis of Crohn's disease (CD) and ulcerative colitis (UC) have led to the development of new treatment options, with a progressive shift to more evidence-based strategies based on sound pathophysiological rationales. A better understanding of inflammatory bowel disease (IBD) pathophysiology has progressively resulted in a more frequent use of immunomodulators. We review the recommended or suggested use of conventional immunomodulators such as azathioprine, 6-mercaptopurine, methotrexate in the treatment of IBD. Moreover, an effort is made to explore some critical areas in which early and more diffuse use of these agents may be advocated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.